# Curated extraction from Immatics pipeline image on https://immatics.com/our-pipeline/
# This is used because the primary pipeline visualization is an image, not an HTML table.
# The system stores the image as Evidence and links these rows to that Evidence.

assets:
  - name: anzu-cel (IMA203)
    modality: Cell therapy
    target: PRAME
    aliases:
      - anzu-cel
      - anzu-cel (anzutresgene autoleucel)
      - anzu-tresgene autoleucel
      - anzu tresgene autoleucel
      - IMA203
    indications:
      - indication: 2L melanoma
        stage: Phase 1
        therapeutic_area: Oncology
      - indication: Uveal melanoma
        stage: Phase 1
        therapeutic_area: Oncology
      - indication: Solid cancers (in combination with mRNA-4203)
        stage: Phase 1
        therapeutic_area: Oncology

  - name: mRNA-4203
    modality: Combination (mRNA)
    target: PRAME
    aliases:
      - mRNA-4203
    indications:
      - indication: Solid cancers (combo with anzu-cel / IMA203)
        stage: Phase 1
        therapeutic_area: Oncology

  - name: IMA203CD8
    modality: Cell therapy
    target: PRAME
    aliases:
      - IMA203CD8
    indications:
      - indication: Gynecologic cancers; other solid cancers
        stage: Phase 1
        therapeutic_area: Oncology

  - name: IMA402
    modality: Bispecific (TCER)
    target: PRAME
    aliases:
      - IMA402
    indications:
      - indication: Melanoma, gynecologic cancers, other solid cancers
        stage: Phase 1
        therapeutic_area: Oncology

  - name: IMA402 + ICI
    modality: Bispecific (TCER) + checkpoint inhibitor
    target: PRAME
    aliases:
      - IMA402 + ICI
    indications:
      - indication: Melanoma, gynecologic cancers, other solid cancers (combo)
        stage: Phase 1
        therapeutic_area: Oncology

  - name: IMA401
    modality: Bispecific (TCER)
    target: MAGEA4/8
    aliases:
      - IMA401
    indications:
      - indication: HNSCC, sqNSCLC, other solid cancers
        stage: Phase 1
        therapeutic_area: Oncology

  - name: Undisclosed bispecific
    modality: Bispecific (TCER)
    target: other
    is_disclosed: false
    indications:
      - indication: Undisclosed
        stage: Preclinical
        therapeutic_area: Oncology

  - name: Undisclosed cell therapy
    modality: Cell therapy
    target: other
    is_disclosed: false
    indications:
      - indication: Undisclosed
        stage: Preclinical
        therapeutic_area: Oncology
